• DARRT-1 provides evidence of more abscopal responses
• Meeting of US Advisory Board in Philadelphia
Sydney, 8 August 2018 : Noxopharm (ASX:NOX) today provides a shareholder update on the Company’s DARRT clinical program.
The company convened a meeting of a US Medical Advisory Board in Philadelphia on Monday August 6th. The Board comprised 10 leading medical and radiation oncologists from major US hospitals. The purpose of the meeting was to consider the early clinical data relating to the DARRT program, and to provide guidance on a strategy of bringing DARRT to market.
For further information please download PDF attached:
Download this document
